Breathlessness

At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab vs. placebo showed more improved symptom scores, according to a poster presented at the European Respiratory Society International Congress.

SAN DIEGO — Among patients with moderate to severe COPD, 24-week ensifentrine improved dyspnea, according to research presented at the American Thoracic Society International Conference.

Use of gaseous household fuels vs. polluting fuels for cooking and heating lowered an individual’s odds for COPD, wheeze and severe respiratory illness/death, according to study results published in Lancet Respiratory Medicine.

Patients with COPD who experience breathlessness and exertional desaturation may see improvements with use of an oral positive expiratory device, according to study results published in Respiratory Care.

A model that factors in brain imaging markers of breathlessness expectation, questionnaires and physiology measures predicted changes in breathlessness during pulmonary rehabilitation, according to study results published in Thorax.

An online breathing and well-being program improved health-related quality of life and persistent breathlessness in individuals with ongoing symptoms following COVID-19, researchers reported in The Lancet Respiratory Medicine.

Patients who were hospitalized with COVID-19 may have developed cardiac complications as they continued presenting with dyspnea 1 year after hospital discharge, according to a small study presented at EuroEcho 2021.